Physician’s Profile

Teri N. Kreisl, MD

Department of Neurology
Division of Neuro-oncology
Introduction:

Dr. Teri N. Kreisl earned her medical degree from Weill Medical College of Cornell University. She was Chief Resident of her neurology program at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, then completed fellowship subspecialty training in neuro-oncology at Memorial Sloan-Kettering Cancer Center.

Subsequently, Dr. Kreisl joined the Neuro-Oncology Branch (NOB) of the Center for Cancer Research at the National Cancer Institute where she was a Tenure Track Clinical Investigator with a research focus on molecular imaging in brain tumors. Dr. Kreisl also served as Fellowship Director and Medical Director for the NOB.

She has experience as Principal Investigator for numerous phase I and II clinical trials for the treatment of primary brain tumors, and will continue similar research efforts with the Division of Neuro-oncology at Columbia University.

Board Certificates
Neurology
Areas of Expertise:
  • Neuro-Oncology
  • Cancer Care
  • Brain & Spinal Tumors
  • Acoustic Neuroma
  • Anaplastic Astrocytoma
  • Astrocytoma
  • Brain Cancer
  • Brain Tumor
  • Brain Metastases
  • Brain Stem Glioma
  • Carcinomatous meningitis
  • Chordoma
  • Choroid Plexus Carcinoma
  • Choroid Plexus Papilloma
  • Ependymoma
  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliomas
  • Hemangioblastoma
  • Leptomeningeal metastases
  • Medulloblastoma
  • Meningioma
  • Metastatic Cancer
  • Mixed Glioma
  • Neurofibromatosis
  • Oligoastrocytoma
  • Oligodendroglioma
  • Spinal Tumors
  • Spinal Cord Tumor
  • Second Opinion
Publications:

ORIGINAL, PEER REVIEWED ARTICLES
Selesnick SH, Nguyen TD, Gutin PH, Lavyne MH. Posterior petrous face meningiomas. Otolaryngol Head Neck Surg. 2001 Apr;124(4):408-13.

Lorenzl S, Albers DS, Relkin N, Nguyen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int. 2003 Aug;43(3):191-6.

Nguyen TD, Abrey LE. Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol. 2007 May;5(5):375-6; discussion 377-9.

Kreisl TN, Toothaker T, Karimi S, DeAngelis LM. Ischemic stroke in patients with primary brain tumors. Neurology. 2008 Jun 10;70(24):2314-20.

Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma. 2008 Sep;49(9):1710-6.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009 Feb 10;27(5):740-5.

Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009 Mar;92(1):99-105.

Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res. 2009 May 15;15(10):3617-23.

Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010 Feb;12(2):181-9.

Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 2010 Apr 1;116(7):1776-82.

Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010 Aug 20;28(24):3838-43.

Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology. 2011 Jan 18;76(3):236-41.

Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol. 2011 Oct;13(10):1143-50.

Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol. 2011 Nov;105(2):281-9.

Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol. 2012 Dec;14(12):1519-26.

Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013 Jan;111(1):41-8.

Ho J, Ondos J, Ning H, Smith S, Kreisl T, Iwamoto F, Sul J, Kim L, McNeil K, Krauze A, Shankavaram U, Fine HA, Camphausen K. Chemoirradiation for glioblastoma multiforme: the National Cancer Institute experience. PLoS One. 2013;8(8):e70745.

Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 30;942-943:107-12.

REVIEWS
Nguyen T, Deangelis LM. Treatment of brain metastases. J Support Oncol. 2004 Sep-Oct;2(5):405-10; discussion 411-6.

Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep. 2006 May;6(3):187-92.

Nguyen TD, Abrey LE. Brain metastases: old problem, new strategies. Hematol Oncol Clin North Am. 2007 Apr;21(2):369-88.

Nguyen TD, DeAngelis LM. Brain metastases. Neurol Clin. 2007 Nov;25(4):1173-92, x-xi.

Kreisl TN. Neurologic complications of antitumor antibody therapies. Curr Neurol Neurosci Rep. 2008 May;8(3):259-63.

Kreisl TN. Chemotherapy for malignant gliomas. Semin Radiat Oncol. 2009 Jul;19(3):150-4.

*Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther. 2010 Jun 24;3